JPH06503477A - 真核無細胞抽出物中での転写と翻訳の共役 - Google Patents
真核無細胞抽出物中での転写と翻訳の共役Info
- Publication number
- JPH06503477A JPH06503477A JP5507150A JP50715093A JPH06503477A JP H06503477 A JPH06503477 A JP H06503477A JP 5507150 A JP5507150 A JP 5507150A JP 50715093 A JP50715093 A JP 50715093A JP H06503477 A JPH06503477 A JP H06503477A
- Authority
- JP
- Japan
- Prior art keywords
- translation
- extract
- added
- concentration
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000013519 translation Methods 0.000 title claims description 155
- 238000013518 transcription Methods 0.000 title claims description 95
- 230000035897 transcription Effects 0.000 title claims description 95
- 239000000284 extract Substances 0.000 title claims description 76
- 238000005859 coupling reaction Methods 0.000 title claims description 25
- 230000008878 coupling Effects 0.000 title claims description 16
- 238000010168 coupling process Methods 0.000 title claims description 16
- 238000000034 method Methods 0.000 claims description 121
- 108090000623 proteins and genes Proteins 0.000 claims description 107
- 239000006166 lysate Substances 0.000 claims description 88
- 102000004169 proteins and genes Human genes 0.000 claims description 76
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 55
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 53
- 239000011777 magnesium Substances 0.000 claims description 53
- 229910052749 magnesium Inorganic materials 0.000 claims description 53
- 241000209140 Triticum Species 0.000 claims description 42
- 235000021307 Triticum Nutrition 0.000 claims description 42
- 210000001995 reticulocyte Anatomy 0.000 claims description 42
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 39
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical group NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims description 32
- 238000010367 cloning Methods 0.000 claims description 26
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 16
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 16
- 229940063673 spermidine Drugs 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 13
- 239000001226 triphosphate Substances 0.000 claims description 13
- 235000011178 triphosphate Nutrition 0.000 claims description 13
- 108091028664 Ribonucleotide Proteins 0.000 claims description 11
- 229920000768 polyamine Polymers 0.000 claims description 11
- 239000002336 ribonucleotide Substances 0.000 claims description 11
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 9
- 102000006382 Ribonucleases Human genes 0.000 claims description 9
- 108010083644 Ribonucleases Proteins 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 9
- 239000011591 potassium Substances 0.000 claims description 9
- 229910052700 potassium Inorganic materials 0.000 claims description 9
- 230000021615 conjugation Effects 0.000 claims description 8
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 8
- 239000003161 ribonuclease inhibitor Substances 0.000 claims description 7
- 239000000155 melt Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 6
- -1 ribonucleotide triphosphates Chemical class 0.000 claims description 6
- 101710137500 T7 RNA polymerase Proteins 0.000 claims description 5
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 3
- 150000002681 magnesium compounds Chemical class 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 2
- 101710141795 Ribonuclease inhibitor Proteins 0.000 claims 6
- 229940122208 Ribonuclease inhibitor Drugs 0.000 claims 6
- 102100037968 Ribonuclease inhibitor Human genes 0.000 claims 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 4
- 108010065868 RNA polymerase SP6 Proteins 0.000 claims 4
- 238000003752 polymerase chain reaction Methods 0.000 claims 4
- 238000006116 polymerization reaction Methods 0.000 claims 4
- 229940122014 Lyase inhibitor Drugs 0.000 claims 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 2
- 239000002697 lyase inhibitor Substances 0.000 claims 2
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 230000014616 translation Effects 0.000 description 155
- 238000006243 chemical reaction Methods 0.000 description 93
- 108020004414 DNA Proteins 0.000 description 51
- 238000000338 in vitro Methods 0.000 description 44
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 24
- 210000003527 eukaryotic cell Anatomy 0.000 description 16
- 239000000872 buffer Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 108020004999 messenger RNA Proteins 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 12
- 239000011654 magnesium acetate Substances 0.000 description 12
- 235000011285 magnesium acetate Nutrition 0.000 description 12
- 229940069446 magnesium acetate Drugs 0.000 description 12
- 235000011056 potassium acetate Nutrition 0.000 description 12
- 239000013592 cell lysate Substances 0.000 description 11
- 230000003068 static effect Effects 0.000 description 11
- 108060001084 Luciferase Proteins 0.000 description 10
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000007792 addition Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000003228 microsomal effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000000376 reactant Substances 0.000 description 6
- 206010046865 Vaccinia virus infection Diseases 0.000 description 5
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 208000007089 vaccinia Diseases 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 210000004671 cell-free system Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229940025294 hemin Drugs 0.000 description 3
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229950007002 phosphocreatine Drugs 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 235000019687 Lamb Nutrition 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108091028733 RNTP Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000007771 core particle Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000007030 peptide scission Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 101100072149 Drosophila melanogaster eIF2alpha gene Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 241001071861 Lethrinus genivittatus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101001050287 Mus musculus Transcription factor Jun Proteins 0.000 description 1
- 241001553014 Myrsine salicina Species 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 241000791420 Plica Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 235000008853 Zanthoxylum piperitum Nutrition 0.000 description 1
- 244000131415 Zanthoxylum piperitum Species 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000006122 isoprenylation Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000010667 large scale reaction Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012803 melt mixture Substances 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- FHUOTRMCFQTSOA-UHFFFAOYSA-M potassium;acetic acid;acetate Chemical compound [K+].CC(O)=O.CC([O-])=O FHUOTRMCFQTSOA-UHFFFAOYSA-M 0.000 description 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000005664 protein glycosylation in endoplasmic reticulum Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 230000009712 regulation of translation Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 108010042582 tosylarginine methyl ester hydrolase Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.RNAがDNAから転写され且つRNAがタンパク質に翻訳される水準にマ グネシウム濃度を高めるのに十分な量のマグネシウム化合物を真核無細胞抽出物 に加えることからなる上記抽出物中でDNAからの転写と翻訳を共役させる方法 。 2.上記抽出物がウサギ網状赤血球溶解物である請求項1に記載の方法。 3.上記最終マグネシウム濃度が約2.5mMから約3.5mMである請求項2 に記載の方法。 4.上記最終マグネシウム濃度が約2.6mMから約3.0mMである請求項2 に記載の方法。 5.ポリアミンが上記溶解物に添加される請求項2に記載の方法。 6.上記ポリアミンがスペルミジンである請求項5に記載の方法。 7.上記スペルミジンを上記溶解物に加えて約0.2mMから約0.4mMの濃 度にする請求項6に記載の方法。 8.上記溶解物のカリウム濃度を約40mMから約100mMに調整する請求項 2に記載の方法。 9.内因性リボヌクレアーゼを効果的に不活性化するのに十分な量のリボヌクレ アーゼインヒビターを上記溶解物に添加することを含む請求項2に記載の方法。 10.上記リボヌクレアーゼインヒビターがRNasinである請求項9に記載 の方法。 11.転写と翻訳の共役に必要な追加成分を上記溶解物に添加することを含む請 求項2に記載の方法。 12.上記追加成分の1つがRNAポリメラーゼからなる請求項11に記載の方 法。 13.上記ポリメラーゼがSP6、T7およびT3RNAポリメラーゼからなる 群から選択される請求項12に記載の方法。 14.DNA鋳型が上記溶解物に添加される請求項2に記載の方法。 15.上記DNA鋳型か複数のクローニング領域を有する請求項14に記載の方 法。 16.ポリメラーゼプロモーター配列が上記複数のクローニング領域の1方の末 端に位置している請求項15に記載の方法。 17.上記複数のクローニング領域へのクローニングによってRNAポリメラー ゼプロモーターが5′末端にそしてポリA配列が3′末端に位置する遺伝子が生 じるように、上記鋳型が上記複数のクローニング領域の反対側末端にポリA配列 を有する請求項16に記載の方法。 18.上記プロモーター配列に対応しているポリメラーゼが上記溶解物に添加さ れる請求項16に記載の方法。 19.上記DNA鋳型が、ポリメラーゼ鎖反応として知られる方法によって製造 された超コイル分子、共有的閉環状分子、線状分子またはDNA断片からなる群 から選択される形態である請求項14に記載の方法。 20.DNAからRNAの転写を可能にするのに十分な量のリボヌクレオチド三 リン酸が上記溶解物に添加されることを含む請求項2に記載の方法。 21.上記溶解物に上記リボヌクレオチド三リン酸が各々0.4mM添加される 請求項20に記載の方法。 22.上記抽出物が小麦胚芽抽出物である請求項1に記載の方法。 23.上記最終マグネシウム濃度が約3.0mMから約5.25mMである請求 項22に記載の方法。 24.上記最終マグネシウム濃度が約4.0mMから約4.75mMである請求 項22に記載の方法。 25.ポリアミンが上記抽出物に添加される請求項22に記載の方法。 26.上記ポリアミンがスペルミジンである請求項25に記載の方法。 27.上記スペルミジンを上記抽出物に添加して約0.2mMから0.9mMの 濃度にする請求項26に記載の方法。 28.上記抽出物のカリウム濃度が約50mMから約150mMに調整される請 求項22に記載の方法。 29.内因性リボヌクレアーゼを効果的に不活性化するのに十分な量のリボヌク レアーゼインヒビターが上記溶解物に添加されることを含む請求項22に記載の 方法。 30.上記リボヌクレアーゼインヒビクーがRNasinである請求項29に記 載の方法。 31.転写と翻訳の共役に必要な追加成分が上記溶解物に添加されることを含む 請求項22に記載の方法。 32.上記追加成分の1つがRNAポリメラーゼからなる請求項31に記載の方 法。 33.上記ポリメラーゼがSP6、T7およびT3RNAポリメラーゼからなる 群から選択される請求項32に記載の方法。 34.DNA鋳型か上記抽出物に添加される請求項22に記載の方法。 35.上記DNA鋳型が複数のクローニング領域を有する請求項34に記載の方 法。 36.ポリメラーゼプロモーター配列が上記複数のクローニング領域の1方の末 端に位置している請求項35に記載の方法。 37.上記複数のクローニング領域へのクローニングによってRNAポリメラー ゼプロモーターが5′末端にそしてポリA配列か3′末端に位置する遺伝子が生 じるように、上記鋳型が上記複数のクローニング領域の反対側末端にポリA配列 を有する請求項36に記載の方法。 38.上記プロモーター配列に対応しているポリメラーゼが上記抽出物に添加さ れる請求項36に記載の方法。 39.上記DNA鋳型が、ポリメラーゼ鎖反応として知られる方法によって製造 された超コイル分子、共有的閉環状分子、線状分子またはDNA断片からなる群 から選択される形態である請求項34に記載の方法。 40.DNAからRNAの翻訳を可能にするのに十分な量のリボヌクレオチド三 リン酸が上記抽出物に添加されることを含む請求項22に記載の方法。 41.上記リボヌクレオチド三リン酸が0.4mMのCTP、0.4mMのUT P、0.5mMのGTPおよび1.6mMのATPの値で上記抽出物に添加され る請求項40に記載の方法。 42.請求項1に従って調製された、修正された真核無細胞抽出物、43.請求 項42に記載の抽出物を含有する容器からなるキット。 44.請求項5または請求項25に従って調製された、修正された真核無細胞抽 出物。 45.請求項44に記載の抽出物を含有する容器からなるキット。 46.請求項12または請求項32に従って調製された、修正された真核無細胞 抽出物。 47.請求項46に記載の抽出物を含有する容器からなるキット。 48.特定のポリメラーゼプロモーター配列を有するDNA鋳型から溶液中で転 写と翻訳の共役によってタンパク質を製造する方法であって、該方法は真核無細 胞抽出物の標準的な調製物の溶液を調製し、転写と翻訳を支えるのに十分な濃度 のリボヌクレオチド三リン酸、アミノ酸および上記鋳型DNAの上記プロモータ ーに対応しているポリメラーゼで上記抽出物溶液を修正し、そしてRNAが上記 DNA鋳型から転写され且つ該RNAがタンパク質に翻訳される水準に最終マグ ネシウム濃度を上昇させるのに十分な量のマグネシウム化合物を上記抽出物溶液 に添加することからなる方法。 49.上記抽出物溶液混合物中のマグネシウムの最終濃度が約0.5mM上昇さ せられる請求項48に記載の方法。 50.上記抽出物がウサギ網状赤血球溶解物である請求項48に記載の方法。 51.上記最終マグネシウム濃度が約2.5mMから約3.5mMである請求項 50に記載の方法。 52.上記最終マグネシウム濃度が約2.6mMから約3.0mMである請求項 50に記載の方法。 53.ポリアミンが上記溶液に添加される請求項50に記載の方法。 54.上記ポリアミンがスペルミジンである請求項53に記載の方法。 55.上記スペルミジンを上記溶液に添加して約0.2mMから約0.4mMの 濃度にする請求項54に記載の方法。 56.上記溶液のカリウム濃度が約40mMから約100mMに調整される請求 項50に記載の方法。 57.内因性リボヌクレアーゼを効果的に不活性化するのに十分な量のリボヌク レアーゼインヒビターが上記溶液に添加されることを含む請求項50に記載の方 法。 58.上記リボヌクレアーゼインヒビターがRNasinである請求項57に記 載の方法。 59.転写と翻訳の共役に必要な追加成分が上記溶液に添加されることを含む請 求項50に記載の方法。 60.上記追加成分の1つがRNAポリメラーゼを含む請求項59に記載の方法 。 61.上記ポリメラーゼがSP6、T7およびT3RNAポリメラーゼからなる 群から選択される請求項60に記載の方法。 62.上記DNA鋳型が、ポリメラーゼ鎖反応として知られる方法によって製造 された超コイル分子、共有的閉環状分子、線状分子またはDNA断片からなる群 から選択される形態である請求項50に記載の方法。 63.上記DNA鋳型が複数のクローニング領域を有する請求項50に記載の方 法。 64.ポリメラーゼプロモーター配列が上記複数のクローニング領域の1方の末 端に位置している請求項63に記載の方法。 65.上記複数のクローニング領域へのクローニングによってRNAポリメラー ゼプロモーターが5′末端にそしてポリA配列が3′末端に位置する遺伝子が生 じるように、上記鋳型が上記複数のクローニング領域の反対側末端にポリA配列 を有する請求項64に記載の方法。 66.上記溶液に上記リボヌクレオチド三リン酸が各々0.4mM添加される請 求項50に記載の方法。 67.上記抽出物が小麦胚芽抽出物である請求項48に記載の方法。 68.上記最終マグネシウム濃度が約3.0mMから約5.25mMである請求 項67に記載の方法。 69.上記最終マグネシウム濃度が約4.0mMから約4.75mMである請求 項68に記載の方法。 70.ポリアミンが上記溶液に添加される請求項67に記載の方法。 71.上記ポリアミンがスペルミジンである請求項70に記載の方法。 72.上記溶液に上記スペルミジンを添加して約0.2mMから約0.9mMの 濃度にする請求項71に記載の方法。 73.上記溶液のカリウム濃度が約50mMから約150mMに調整される請求 項67に記載の方法。 74.内因性リボヌクレアーゼを効果的に不活性化するのに十分な量のリボヌク レアーゼインヒビターが上記溶液に添加されることを含む請求項67に記載の方 法。 75.上記リボヌクレアーゼインヒビターがRNasinである請求項74に記 載の方法。 76.転写と翻訳の共役に必要な追加成分が上記溶液に添加されることを含む請 求項67に記載の方法。 77.上記追加成分かRNAポリメラーゼからなる請求項76に記載の方法。 78.上記ポリメラーゼがSP6、T7およびT3RNAポリメラーゼからなる 群から選択される請求項77に記載の方法。 79.上記DNA鋳型が、ポリメラーゼ鎖反応として知られる方法によって製造 された超コイル分子、共有的閉環状分子、線状分子またはDNA断片からなる群 から選択される形態である請求項67に記載の方法。 80.上記DNA鋳型が複数のクローニング領域を有する請求項67に記載の方 法。 81.ポリメラーゼプロモーター配列が上記複数のクローニング領域の1方の末 端に位置している請求項80に記載の方法。 82.上記複数のクローニング領域へのクローニングによってRNAポリメラー ゼプロモーターが5′末端にそしてポリA配列が3′末端に位置する遺伝子が生 じるように、上記鋳型が上記複数のクローニング領域の反対側末端にポリA配列 を有する請求項81に記載の方法。 83.上記リボヌクレオチド三リン酸が0.4mMのCTP、0.4mMのUT P、0.5mMのGTPおよび1.6mMのATPの値で上記溶液に添加される 請求項67に記載の方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77513691A | 1991-10-11 | 1991-10-11 | |
| US775,136 | 1991-10-11 | ||
| PCT/US1992/008518 WO1993007287A1 (en) | 1991-10-11 | 1992-10-07 | Coupled transcription and translation in eukaryotic cell-free extract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH06503477A true JPH06503477A (ja) | 1994-04-21 |
| JP2904583B2 JP2904583B2 (ja) | 1999-06-14 |
Family
ID=25103433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5507150A Expired - Lifetime JP2904583B2 (ja) | 1991-10-11 | 1992-10-07 | 真核無細胞抽出物中での転写と翻訳の共役 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5324637A (ja) |
| EP (1) | EP0566714B1 (ja) |
| JP (1) | JP2904583B2 (ja) |
| AT (1) | ATE147104T1 (ja) |
| AU (1) | AU660329B2 (ja) |
| DE (1) | DE69216385T2 (ja) |
| DK (1) | DK0566714T3 (ja) |
| ES (1) | ES2097363T3 (ja) |
| GR (1) | GR3022719T3 (ja) |
| WO (1) | WO1993007287A1 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000068412A1 (en) * | 1999-05-11 | 2000-11-16 | Wakenyaku Co., Ltd. | Preparation containing cell extract for synthesizing cell-free protein and means for synthesizing cell-free protein |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665563A (en) * | 1991-10-11 | 1997-09-09 | Promega Corporation | Coupled transcription and translation in eukaryotic cell-free extract |
| US5492817A (en) * | 1993-11-09 | 1996-02-20 | Promega Corporation | Coupled transcription and translation in eukaryotic cell-free extract |
| WO1994005812A1 (en) * | 1992-09-02 | 1994-03-17 | The Scripps Research Institute | Coupled isothermal polynucleotide amplification and translation system |
| WO1994006928A1 (en) * | 1992-09-24 | 1994-03-31 | The Public Health Research Institute Of The City Of New York, Inc. | Coupled replication-translation methods and kits for protein synthesis |
| KR0131166B1 (ko) * | 1994-05-04 | 1998-04-11 | 최차용 | 무세포시스템에서 단백질을 제조하는 방법 |
| US5874231A (en) * | 1994-08-22 | 1999-02-23 | Mcgill University | Methods of screening for non-hormone compounds which effect modulation of polypeptide translation |
| AU4230396A (en) * | 1994-11-08 | 1996-05-31 | Novagen, Inc. | Method for in vitro protein synthesis |
| US6077664A (en) * | 1995-06-07 | 2000-06-20 | Promega Corporation | Thermophilic DNA polymerases from Thermotoga neapolitana |
| US6001645A (en) * | 1995-06-07 | 1999-12-14 | Promega Corporation | Thermophilic DNA polymerases from thermotoga neapolitana |
| EP0932686A2 (en) | 1996-10-01 | 1999-08-04 | Geron Corporation | Telomerase reverse transcriptase |
| WO1998035062A1 (en) * | 1997-02-07 | 1998-08-13 | Lingappa Jaisri R | Multistep, atp-dependent cell-free system for the assembly of human immunodeficiency virus capsids |
| US7638269B2 (en) * | 1997-02-07 | 2009-12-29 | The Regents Of The University Of California | Viral capsid assembly intermediates and methods of production |
| US6207370B1 (en) | 1997-09-02 | 2001-03-27 | Sequenom, Inc. | Diagnostics based on mass spectrometric detection of translated target polypeptides |
| US6723564B2 (en) | 1998-05-07 | 2004-04-20 | Sequenom, Inc. | IR MALDI mass spectrometry of nucleic acids using liquid matrices |
| US6168931B1 (en) | 1999-03-17 | 2001-01-02 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced in vitro synthesis of biological macromolecules using a novel ATP regeneration system |
| US6994986B2 (en) | 1999-03-17 | 2006-02-07 | The Board Of Trustees Of The Leland Stanford University | In vitro synthesis of polypeptides by optimizing amino acid metabolism |
| RU2169154C2 (ru) | 1999-03-25 | 2001-06-20 | Институт белка РАН | Способ получения полипептидов в бесклеточной системе |
| US20030091999A1 (en) * | 1999-10-01 | 2003-05-15 | Zhongping Yu | Compositions and methods for identifying polypeptides and nucleic acid molecules |
| US6632645B1 (en) | 2000-03-02 | 2003-10-14 | Promega Corporation | Thermophilic DNA polymerases from Thermoactinomyces vulgaris |
| US6436677B1 (en) * | 2000-03-02 | 2002-08-20 | Promega Corporation | Method of reverse transcription |
| EP1278883B1 (en) * | 2000-05-03 | 2004-12-29 | EMD Biosciences, Inc. | E. coli extract for protein synthesis |
| US6878861B2 (en) * | 2000-07-21 | 2005-04-12 | Washington State University Research Foundation | Acyl coenzyme A thioesterases |
| KR100399337B1 (ko) * | 2001-02-07 | 2003-09-26 | 드림바이오젠 주식회사 | 단백질의 무세포 번역후수식법 |
| DE60222390T2 (de) * | 2001-03-08 | 2008-06-19 | Invitrogen Corp., Carlsbad | Verbessertes in-vitro-synthesesystem |
| WO2003023360A2 (en) | 2001-09-10 | 2003-03-20 | Meso Scale Technologies, Llc | Methods and apparatus for conducting multiple measurements on a sample |
| US8034581B2 (en) * | 2001-11-26 | 2011-10-11 | Toshio Hara | Cell-free extract and glycoprotein synthesis system |
| EP1477566B1 (en) * | 2002-01-31 | 2007-09-26 | CellFree Sciences Co., Ltd. | Germ extract for cell-free protein synthesis and process for producing the same |
| US7744816B2 (en) | 2002-05-01 | 2010-06-29 | Intel Corporation | Methods and device for biomolecule characterization |
| US8278055B2 (en) * | 2002-05-01 | 2012-10-02 | Intel Corporation | Methods and device for analyte characterization |
| CN1738914A (zh) | 2002-11-21 | 2006-02-22 | 震源技术公司 | 使用编码双链启动子一条链的引物的方法 |
| US8779175B2 (en) | 2004-10-25 | 2014-07-15 | Synthonics, Inc. | Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients |
| US20060141054A1 (en) | 2004-10-25 | 2006-06-29 | Thomas Piccariello | Metal coordinated compositions |
| US7799937B2 (en) * | 2004-10-25 | 2010-09-21 | Synthonics, Inc. | Metal coordinated compositions |
| US20080248565A1 (en) * | 2007-03-01 | 2008-10-09 | Invitrogen Corporation | Isolated phospholipid-protein particles |
| US20070117179A1 (en) * | 2005-09-27 | 2007-05-24 | Invitrogen Corporation | In vitro protein synthesis systems for membrane proteins that include adolipoproteins and phospholipid-adolipoprotein particles |
| US20090176654A1 (en) * | 2007-08-10 | 2009-07-09 | Protelix, Inc. | Universal fibronectin type III binding-domain libraries |
| US8680019B2 (en) * | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| US8691730B2 (en) | 2007-09-14 | 2014-04-08 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| EP2494046B1 (en) | 2009-10-30 | 2018-09-12 | Novartis AG | Universal fibronectin type iii bottom-side binding domain libraries |
| EP2561086A1 (en) | 2010-04-20 | 2013-02-27 | Institut Für Mikrotechnik Mainz GmbH | System for the in vitro transcription and translation of membrane proteins |
| DK2593594T3 (en) | 2010-07-16 | 2017-12-11 | Adimab Llc | ANTIBODY LIBRARIES |
| CN107903321A (zh) | 2010-07-30 | 2018-04-13 | 诺华有限公司 | 纤连蛋白摇篮分子和其库 |
| EP3080158A4 (en) | 2013-12-09 | 2018-03-21 | Adimab, LLC | Polyclonal mixtures of antibodies, and methods of making and using them |
| AU2016245887B2 (en) | 2015-04-10 | 2021-09-23 | Adimab, Llc. | Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species |
| US10612031B2 (en) * | 2017-02-09 | 2020-04-07 | Dow Agrosciences Llc | Eukaryotic cell-free protein expression system that does not require an artificial energy regeneration system |
| CN113409887A (zh) * | 2021-07-07 | 2021-09-17 | 中国科学院生物物理研究所 | 一种无细胞翻译体系、方法及产物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1705302A1 (ru) * | 1988-12-22 | 1992-01-15 | Институт Белка Ан Ссср | Способ препаративной экспрессии генов в бесклеточной системе сопр женной транскрипции/трансл ции |
| DK0593757T3 (da) * | 1989-07-31 | 1997-07-07 | Inst Of Protein Research Russi | Fremgangsmåde til opnåelse af polypeptider i et cellefrit system |
-
1992
- 1992-10-07 ES ES92922343T patent/ES2097363T3/es not_active Expired - Lifetime
- 1992-10-07 AU AU27921/92A patent/AU660329B2/en not_active Ceased
- 1992-10-07 EP EP92922343A patent/EP0566714B1/en not_active Revoked
- 1992-10-07 AT AT92922343T patent/ATE147104T1/de not_active IP Right Cessation
- 1992-10-07 WO PCT/US1992/008518 patent/WO1993007287A1/en not_active Ceased
- 1992-10-07 JP JP5507150A patent/JP2904583B2/ja not_active Expired - Lifetime
- 1992-10-07 DE DE69216385T patent/DE69216385T2/de not_active Revoked
- 1992-10-07 DK DK92922343.6T patent/DK0566714T3/da active
-
1993
- 1993-11-09 US US08/149,715 patent/US5324637A/en not_active Expired - Lifetime
-
1997
- 1997-03-03 GR GR970400408T patent/GR3022719T3/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000068412A1 (en) * | 1999-05-11 | 2000-11-16 | Wakenyaku Co., Ltd. | Preparation containing cell extract for synthesizing cell-free protein and means for synthesizing cell-free protein |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1993007287A1 (en) | 1993-04-15 |
| DE69216385T2 (de) | 1997-06-12 |
| ES2097363T3 (es) | 1997-04-01 |
| GR3022719T3 (en) | 1997-06-30 |
| EP0566714A1 (en) | 1993-10-27 |
| EP0566714B1 (en) | 1997-01-02 |
| DK0566714T3 (da) | 1997-06-16 |
| DE69216385D1 (de) | 1997-02-13 |
| AU660329B2 (en) | 1995-06-22 |
| ATE147104T1 (de) | 1997-01-15 |
| AU2792192A (en) | 1993-05-03 |
| US5324637A (en) | 1994-06-28 |
| EP0566714A4 (en) | 1994-07-13 |
| JP2904583B2 (ja) | 1999-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH06503477A (ja) | 真核無細胞抽出物中での転写と翻訳の共役 | |
| US5665563A (en) | Coupled transcription and translation in eukaryotic cell-free extract | |
| US5492817A (en) | Coupled transcription and translation in eukaryotic cell-free extract | |
| US20250066770A1 (en) | Modified transposons, compositions and uses thereof | |
| Oh et al. | Design, assembly, production, and transfection of synthetic modified mRNA | |
| US8372604B2 (en) | Compositions and methods for reverse transcriptase-polymerase chain reaction (RT-PCR) | |
| CN109971775B (zh) | 一种核酸构建物及其调控蛋白合成的方法 | |
| JP7825552B2 (ja) | 非天然ポリペプチドのインビボ合成のための組成物および方法 | |
| JP7058839B2 (ja) | ローリングサークル増幅産物を使用した無細胞タンパク質発現 | |
| JP7093417B2 (ja) | ヌクレアーゼシステムのノッキングアウトによるインビトロ生合成活性の調節方法 | |
| CN1757724A (zh) | 具有独特特异性的多个重组位点在重组克隆中的用途 | |
| US10407713B2 (en) | Reagent usable for the isolation and/or purification of nucleic acids | |
| US20040121346A1 (en) | Designing and construction of transcription template for synthesizing cell-free protein, and dilution batch-type method of synthesizing cell-free wheat germ protein by using the same | |
| WO2001083805A2 (en) | Improved e. coli extract for protein synthesis | |
| JP6440820B2 (ja) | 無細胞タンパク質合成系に用いるための翻訳促進剤及びその利用 | |
| EP0795027A1 (en) | Method for in vitro protein synthesis | |
| Menacho-Melgar et al. | Improved, scalable, two-stage, autoinduction of recombinant protein expression in E. coli utilizing phosphate depletion | |
| EP4363601A1 (en) | Soybean and maize cell-free expression systems | |
| Cooper | In vivo SELEX in vertebrate cells | |
| Drwesh | In vitro translation in yeast extract to study interactions with cytosolic chaperones | |
| JP4787488B2 (ja) | 直鎖状鋳型dnaを用いた無細胞タンパク質合成方法及びそのための細胞抽出液 | |
| Heuvel | Cloning by PCR | |
| Vanden Heuvel | Cloning by FCR | |
| Tian | Loss of DNA Dependent RNA Polymerase IV’s Fourth and Seventh Subunits Disrupts RNA Directed DNA Methylation Functions But Not Pol IV’s Catalytic Activity | |
| JP2002522093A (ja) | 核酸を含む生物学的標本中に潜在的に存在する機能の分離及び特徴づけ方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090326 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100326 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100326 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110326 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120326 Year of fee payment: 13 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120326 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130326 Year of fee payment: 14 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130326 Year of fee payment: 14 |